hit counter
Cara Therapeutics, Inc. (CARA) Stock News Sentiment & Price - Sentifly
CARA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cara Therapeutics, Inc. (CARA)

USA
Biotechnology
NASDAQ
CARA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CARA Latest news
GlobeNewsWire
Neutral
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
2021-10-04 07:00

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. Results were presented by Brian Kim, MD, Associate Professor of Dermatology and Co-Director of the Center for the Study of Itch and Sensory Disorders at Washington University School of Medicine, during the Late Breaking News session of the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 2, 2021.

GlobeNewsWire
Neutral
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
2021-09-29 07:00

Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presented Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presented

GlobeNewsWire
Neutral
Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference
2021-09-24 07:00

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m. ET.

The Motley Fool
Positive
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
2021-09-04 08:55

There's good news at long last for the beaten-down biotech stock.

Benzinga
Neutral
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
2021-08-31 14:00

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

The Motley Fool
Positive
Why Cara Therapeutics Shot Higher Today
2021-08-24 16:08

The biotech gets an important nod from a top regulator.

InvestorPlace
Positive
CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today
2021-08-24 15:43

Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. The post CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today appeared first on InvestorPlace.

Schaeffers Research
Positive
Biotech Stock Takes on Technical Ceiling After FDA Okay
2021-08-24 14:13

Care Therapeutics Inc (NASDAQ:CARA) is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration (FDA) approved its Korsuva difelikefalin injection to treat moderate-to-severe itching in adult patients with chronic kidney disease undergoing dialysis.

Zacks Investment Research
Positive
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
2021-08-24 12:59

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Benzinga
Positive
Why Is Cara Therapeutics Stock Trading Higher Today?
2021-08-24 10:57

Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. KORSUVA injection is a kappa opioid receptor agonist that targets the body's peripheral nervous system.

Loading more news...